- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02733198
Prognostication in Acute Pulmonary Embolism (IPEP)
Effect of a Prognostic Algorithm to Reduce Length of Stay in Acute Pulmonary Embolism: a Randomized Controlled Trial
To evaluate the effect of a prognosis-guided vs standard medical therapy in the: 1) duration of hospital stay; 2) cost-effectiveness; 3) satisfaction and quality of life; 4) in-hospital and 30-day all-cause mortality; and 5) 30-day readmissions in normotensive patients with acute symptomatic pulmonary embolism (PE).
Design: Prospective, randomized, controlled, single blind trial. Normotensive patients with acute symptomatic PE will be randomly assigned to follow a prognosis-guided treatment, or to receive usual care.
Setting: Respiratory, Medicine and Emergency Departments in 15 Spanish hospitals.
Analyses: Data for the primary and secondary end points will be analyzed according to the intention-to -treat principle. The intention-to-treat analysis will include all randomly assigned patients. For the efficacy end points, investigators will use the Mann-Whitney U test. We will also use competing risk regression models according to Fine and Gray. For the safety end points, comparisons will be made with the use of the chi-square test. Separate analyses will be done in key prespecified subgroups of patients, according to age and hospital size.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28034
- Hospital Ramon y Cajal, IRYCIS, Alcala de Henares University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmed PE by objective testing
- Signed and dated informed consent of the subject available before the start of any specific trial procedures
Exclusion Criteria:
- Pregnancy
- Haemodynamic instability
- Contraindication to anticoagulant therapy
- Life expectancy less than 3 months
- Participation in other clinical trials during the present clinical trial
- Use of a fibrinolytic agent, surgical thrombectomy, interventional (transcatheter) thrombus aspiration or lysis, or use of a cava filter to treat the index episode of PE
- Inability to the follow-up visits
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prognosis-guided
Duration of bed rest and duration of length of stay will be guided according to a predefined prognostic algorithm.
|
|
No Intervention: Standard medical therapy
Duration of bed rest and duration of length of stay will be decided by the attending physician.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Length of hospital stay
Time Frame: 30-days
|
30-days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Jimenez D, Rodriguez C, Pintado B, Perez A, Jara-Palomares L, Lopez-Reyes R, Ruiz-Artacho P, Garcia-Ortega A, Bikdeli B, Lobo JL; IPEP investigators. Effect of Prognostic Guided Management of Patients With Acute Pulmonary Embolism According to the European Society of Cardiology Risk Stratification Model. Front Cardiovasc Med. 2022 Apr 12;9:872115. doi: 10.3389/fcvm.2022.872115. eCollection 2022.
- Jimenez D, Rodriguez C, Leon F, Jara-Palomares L, Lopez-Reyes R, Ruiz-Artacho P, Elias T, Otero R, Garcia-Ortega A, Rivas-Guerrero A, Abelaira J, Jimenez S, Muriel A, Morillo R, Barrios D, Le Mao R, Yusen RD, Bikdeli B, Monreal M, Lobo JL; IPEP investigators. Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism. Eur Respir J. 2022 Feb 10;59(2):2100412. doi: 10.1183/13993003.00412-2021. Print 2022 Feb.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI15/00207
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Embolism
-
Boston Scientific CorporationEKOS CorporationCompletedPulmonary Embolism | Acute Pulmonary Embolism | Pulmonary Thromboembolism | Massive Pulmonary Embolism | Sub-massive Pulmonary EmbolismUnited States
-
Inari MedicalCompletedPulmonary Embolism | Submassive Pulmonary Embolism | Acute Pulmonary Embolism | Massive Pulmonary EmbolismUnited States
-
University of California, Los AngelesEnrolling by invitationPulmonary Disease | Pulmonary Embolism | Pulmonary Embolus/Emboli | Pulmonary Embolism and Thrombosis | Pulmonary Embolism Subacute Massive | Pulmonary Embolism Acute MassiveUnited States
-
Hospital San Carlos, MadridAsociación de Cardiología Intervencionista de la Sociedad Española de CardiologíaRecruitingPulmonary Embolism | Pulmonary Embolism and Thrombosis | Pulmonary Thromboembolisms | Pulmonary Embolism Acute | Pulmonary Embolism Acute MassiveSpain
-
Inari MedicalActive, not recruitingPE - Pulmonary Embolism | PE - Pulmonary ThromboembolismUnited States, Spain, Belgium, Germany, France, Switzerland, Netherlands, United Kingdom, Austria
-
Bristol-Myers SquibbCompletedPulmonary Embolism (PE) | Pulmonary ThromboembolismUnited Kingdom
-
GlaxoSmithKlineCompleted
-
Sociedad Española de Neumología y Cirugía TorácicaCompletedPulmonary Hypertension | Pulmonary ThromboembolismsSpain
-
Victor Tapson, MDBristol-Myers SquibbTerminatedPulmonary Embolism | Right Ventricular Dysfunction | Right Ventricular Failure | Pulmonary Embolism With Acute Cor Pulmonale | Pulmonary Embolism With Pulmonary Infarction | Pulmonary Embolism Subacute MassiveUnited States
-
Imperative Care, Inc.RecruitingCardiovascular Diseases | Vascular Diseases | Embolism | Thrombosis | Thromboembolism | Acute Pulmonary Embolism | Thrombus; Embolism | Emboli, PulmonaryUnited States
Clinical Trials on Prognosis-guided therapy
-
Azienda Ospedaliero-Universitaria CareggiCompletedNeurological Prognosis Cardiac ArrestItaly
-
Selcuk UniversityCompletedCOVID-19 | Mortality | FrailtyTurkey
-
University of ChicagoUnknownKnowledge, Attitudes, Practice
-
The First Affiliated Hospital of Soochow UniversityCompletedRisk Factor, Cardiovascular | Cardio-Renal Syndrome | Viral Myocarditis
-
University of MalagaCompletedChronic Musculoskeletal PainSpain
-
Corporacion Parc TauliUnknownRenal Cell Carcinoma | Progression | Lymphocyte Disorder | Monocytosis | Local DiseaseSpain
-
Ruijin HospitalNot yet recruitingHospital-acquired Pneumonia | Antibiotic Resistant Infection
-
Assistance Publique - Hôpitaux de ParisEcole Normale Supérieure de ParisRecruitingHeart Arrest | Coma | Cardiopulmonary ResuscitationFrance
-
University of MalagaCompleted
-
University of MalagaCompleted